Lytix Biopharma AS (OSL:LYTIX)
Norway
· Delayed Price · Currency is NOK 9.50
0.00 (0.00%)
Mar 9, 2026, 4:25 PM CET
Lytix Biopharma AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | - | 11.13 | 3.99 | 11.03 | 19.31 | Upgrade
|
| Revenue | - | 11.13 | 3.99 | 11.03 | 19.31 | Upgrade
|
| Revenue Growth (YoY) | - | 178.98% | -63.82% | -42.86% | 373.91% | Upgrade
|
| Gross Profit | - | 11.13 | 3.99 | 11.03 | 19.31 | Upgrade
|
| Selling, General & Admin | 32.62 | 22.63 | 24.37 | 20.41 | 31.1 | Upgrade
|
| Research & Development | 13.8 | 72.57 | 63.17 | 45.61 | 23.74 | Upgrade
|
| Other Operating Expenses | 16.6 | 10.92 | 12.28 | 9.76 | 12.01 | Upgrade
|
| Operating Expenses | 64.03 | 107.03 | 100.78 | 76.7 | 67.29 | Upgrade
|
| Operating Income | -64.03 | -95.9 | -96.79 | -65.67 | -47.99 | Upgrade
|
| Interest Expense | -0.21 | -0.13 | -0.06 | -0.15 | -0.07 | Upgrade
|
| Interest & Investment Income | 2.33 | 1.51 | 2.35 | 1.41 | 0.14 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.17 | -0.08 | 4.01 | 7.72 | -0.17 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.76 | 0.33 | 2.59 | 0.61 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 | Upgrade
|
| Pretax Income | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 | Upgrade
|
| Earnings From Continuing Operations | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 | Upgrade
|
| Net Income | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 | Upgrade
|
| Net Income to Common | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 | Upgrade
|
| Shares Outstanding (Basic) | 68 | 54 | 40 | 40 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 68 | 54 | 40 | 40 | 33 | Upgrade
|
| Shares Change (YoY) | 26.05% | 35.05% | 1.01% | 19.50% | 26.57% | Upgrade
|
| EPS (Basic) | -0.88 | -1.74 | -2.19 | -1.41 | -1.45 | Upgrade
|
| EPS (Diluted) | -0.88 | -1.74 | -2.19 | -1.41 | -1.45 | Upgrade
|
| Free Cash Flow | -59.85 | -70.37 | -96.02 | -52.78 | -44.61 | Upgrade
|
| Free Cash Flow Per Share | -0.88 | -1.30 | -2.40 | -1.33 | -1.34 | Upgrade
|
| Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | -861.29% | -2425.08% | -595.28% | -248.54% | Upgrade
|
| Profit Margin | - | -846.64% | -2202.38% | -508.29% | -249.02% | Upgrade
|
| Free Cash Flow Margin | - | -632.05% | -2405.86% | -478.47% | -231.04% | Upgrade
|
| EBITDA | -63.99 | -95.83 | -96.72 | -65.64 | -47.53 | Upgrade
|
| EBITDA Margin | - | - | - | - | -246.20% | Upgrade
|
| D&A For EBITDA | 0.04 | 0.07 | 0.06 | 0.03 | 0.45 | Upgrade
|
| EBIT | -64.03 | -95.9 | -96.79 | -65.67 | -47.99 | Upgrade
|
| EBIT Margin | - | - | - | - | -248.54% | Upgrade
|
| Revenue as Reported | - | 11.13 | 3.99 | 11.03 | 19.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.